CATAPRES

This brand name is authorized in United States. It is also authorized in Australia, Ireland, Japan, Malta, New Zealand, UK.

Active ingredients

The drug CATAPRES contains one active pharmaceutical ingredient (API):

1	Clonidine UNII W76I6XXF06 - CLONIDINE HYDROCHLORIDE
	Clonidine has been shown to have both central and peripheral sites of action. With long-term treatment clonidine reduces the responsiveness of peripheral vessels to vasoconstrictor and vasodilator substances and to sympathetic nerve stimulation. Early in treatment, however, blood pressure reduction is associated with a central reduction of sympathetic outflow and increased vagal tone.
	Read more about Clonidine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CATAPRES Tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)
CATAPRES Solution for injection	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C02AC01	Clonidine	C Cardiovascular system → C02 Antihypertensives → C02A Antiadrenergic agents, centrally acting → C02AC Imidazoline receptor agonists
Discover more medicines within C02AC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	3141H, 3145M
GB	Medicines & Healthcare Products Regulatory Agency	16313, 27799
IE	Health Products Regulatory Authority	16690, 82872
JP	医薬品医療機器総合機構	2149001F1034, 2149001F2065
MT	Medicines Authority	AA1442/00101, AA565/02803
NZ	Medicines and Medical Devices Safety Authority	810, 811, 812, 813, 814
US	FDA, National Drug Code	0597-0006, 0597-0007, 0597-0011, 0597-0031, 0597-0032, 0597-0033